Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Concert Pharmaceuticals, a clinical stage biotechnology company, has appointed Steven Bernitz as its new senior vice president and chief business officer. Mr Bernitz replaces Jeffrey Williams who now serves as a consultant to the company.
Subscribe to our email newsletter
In this role, Mr Bernitz will be a member of Concert’s executive management team, designing and implementing strategic planning initiatives and having overall responsibility for Concert’s business development activities.
Most recently Mr Bernitz served as CEO of Histogenics. Mr Bernitz has received his BS from Tufts University and an MBA from the J L Kellogg Graduate School of Management at Northwestern University.
Roger Tung, president and CEO of Concert Pharmaceuticals, said: “Steve brings a strong skill set to Concert as well as a proven track record of success in the biotechnology industry. We expect him to play a key role across Concert’s corporate and business development activities.”